Clinical Trial Update: Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

This update notes the termination of a Phase 3 trial evaluating gemcitabine with or without dalteparin in unresectable or metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Venous Thromboembolism

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)
• Gemzar (gemcitabine)

Snippet

Sponsor: Gary Morrow | Conditions: Pancreatic Cancer, Thromboembolism | Phase 3 | Status: TERMINATED